TCGA-78-7167-01A-11R-2066-07
— · cohortA2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA2
- subtype
- cohortA2
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- FATTY_ACID_METABOLISM+0.280
- WNT_BETA_CATENIN_SIGNALING+0.260
- TGF_BETA_SIGNALING+0.200
- ADIPOGENESIS+0.160
- PEROXISOME+0.150
- PROTEIN_SECRETION+0.110
- HEME_METABOLISM+0.090
- NOTCH_SIGNALING+0.070
- UV_RESPONSE_DN+0.070
- OXIDATIVE_PHOSPHORYLATION+0.030
Top 10 suppressed
- E2F_TARGETS-0.610
- INTERFERON_GAMMA_RESPONSE-0.560
- G2M_CHECKPOINT-0.550
- INFLAMMATORY_RESPONSE-0.550
- IL6_JAK_STAT3_SIGNALING-0.530
- ALLOGRAFT_REJECTION-0.520
- INTERFERON_ALPHA_RESPONSE-0.520
- TNFA_SIGNALING_VIA_NFKB-0.510
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- MTORC1_SIGNALING-0.420
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-MP-A5C7-01A-11R-A262-07 | — | cohortA2 | 0.932 |
| 2 | TCGA-78-7156-01A-11R-2039-07 | — | cohortA2 | 0.915 |
| 3 | C3N-02973 | — | cohortA1 | 0.908 |
| 4 | TCGA-55-8087-01A-11R-2241-07 | — | cohortA1 | 0.892 |
| 5 | C3L-03721 | — | cohortA2 | 0.887 |
| 6 | SRR8943006 | — | — | 0.875 |
| 7 | SRR1516058 | — | — | 0.871 |
| 8 | TCGA-A2-A4S0-01A-21R-A266-07 | — | B | 0.868 |
| 9 | C3L-03726 | — | cohortA2 | 0.867 |
| 10 | ERR2278853 | — | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.110 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.070 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.030 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.030 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.010 | Inavolisib | — uncovered |